About Corinth Medtech
Corinth Medtech is a company based in Cupertino (United States) founded in 2014. Corinth Medtech has raised $12 million across 1 funding round from investors including ShangBay Capital. The company has 10 employees as of December 31, 2022. Corinth Medtech operates in a competitive market with competitors including Francis Medical, Radionetics, Hinova Pharmaceuticals, Convergent Therapeutics and Nymox Pharmaceutical, among others.
- Headquarter Cupertino, United States
- Employees 10 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Corinth Medtech, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$12 M (USD)
in 1 rounds
-
Latest Funding Round
$12 M (USD), Series D
Jun 21, 2019
- Investors
-
Employee Count
10
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Corinth Medtech
Corinth Medtech has successfully raised a total of $12M through 1 strategic funding round. The most recent funding activity was a Series D round of $12 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Corinth Medtech
Corinth Medtech has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include ShangBay Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked |
Investor details for Corinth Medtech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Corinth Medtech
Investment portfolio details for Corinth Medtech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Corinth Medtech
Detailed financials for Corinth Medtech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Corinth Medtech Comparisons
Peer comparison for Corinth Medtech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Corinth Medtech
Corinth Medtech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Francis Medical, Radionetics, Hinova Pharmaceuticals, Convergent Therapeutics and Nymox Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of a therapeutic solution to treat prostate, kidney, and bladder cancer
|
|
| Locked | Locked | Locked |
Peptide-targeted radiopharmaceuticals for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Develops small molecule based drug for multiple disease treatment
|
|
| Locked | Locked | Locked |
Cancer therapeutics are developed using dual-targeted radionuclide therapy.
|
|
| Locked | Locked | Locked |
Provides research and development of novel drugs and diagnostic products for the aging population
|
|
| Locked | Locked | Locked |
Immunotherapies for prostate cancer treatment are developed.
|
Detailed competitors of Corinth Medtech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Corinth Medtech
Complete news archive for Corinth Medtech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Corinth Medtech
Corinth Medtech was founded in 2014 and raised its 1st funding round 5 years after it was founded.
Corinth Medtech is headquartered in Cupertino, United States. It is registered at Cupertino, California, United States.
Corinth Medtech is a funded company, having raised a total of $12M across 1 funding round to date.
As of Dec 31, 2022, the latest employee count at Corinth Medtech is 10.
Corinth MedTech is a medical device startup company developing a bipolar transurethral resection system intended for controlled tissue chip resection and coagulation, and removal of prostate adenomas via suction channel under continuous flow conditions following resection using a bipolar resecting device. The device facilitates endoscopically controlled prostate tissue removal for male patients diagnosed with benign prostatic hyperplasia (BPH). The system includes a compact controller with a single-use fluid control system which includes irrigation and aspiration, a single-use resecting device, continuous-flow optical obturator, and sheath. The system is compatible with standard 4mm endoscopes currently used in transurethral resection procedures. The device received FDA 510(k) clearance in March 2017 (K162979).
Corinth Medtech's top competitors include Francis Medical, Radionetics and Nuage Therapeutics.
Corinth Medtech has 1 investor. Key investors include ShangBay Capital.